Drug intelligence / Profile preview

MDNA19 + MDNA413

Development stage: Preclinical
Lead developer: Medicenna Therapeutics
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

MDNA19 + MDNA413 is an investigational **dual-cytokine biologic immunotherapy** from Medicenna that combines the IL-2 super-agonist MDNA19 with the IL-13 super-antagonist MDNA413 in a single BiSKITs-derived construct. The molecule is designed to both stimulate anti-tumor immunity and suppress pro-tumoral type 2 immune signaling: MDNA19 selectively signals through the intermediate-affinity interleukin-2 receptor complex composed of CD122 and CD132 to drive a pro-inflammatory anti-cancer response, while MDNA413 blocks IL-4 and IL-13 signaling through the type 2 IL-4 receptor complex containing IL-4R and IL-13R1. The program has been described as a DUal CytoKine for cancer and has been positioned for treatment of immunologically cold tumors, with preclinical data reported by 2021.

Other names: DUCK Cancer

Targets

IL2RB (IL-2 receptor beta chain)IL-4R type II (Interleukin-4 receptor type II)

Beyond the preview

Go deeper on MDNA19 + MDNA413.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDNA19 + MDNA413.

Explore the full profile